Treatment with anti-CGRP monoclonal antibodies in patients with idiopathic intracranial hypertension: a pilot study

被引：0
|
作者：
Krajnc, N. [1 ]
Macher, S. [1 ]
Marik, W. [2 ]
Michl, M. [3 ]
Novak, K. [4 ]
Woeber, C. [1 ]
Pemp, B. [3 ]
Bsteh, G. [1 ]
机构：
[1] Med Univ Vienna, Dept Neurol, Vienna, Austria
[2] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[3] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria
[4] Med Univ Vienna, Dept Neurosurg, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-253
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [41] Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine
    Lu, Lingyun
    Liu, Meijun
    Hu, Songshan
    Liu, Yao
    Yang, Dongdong
    Hong, Peiwei
    DRUGS OF THE FUTURE, 2017, 42 (10) : 609 - 615
  • [42] Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
    Kristian Agmund Haanes
    Lars Edvinsson
    Anette Sams
    The Journal of Headache and Pain, 2020, 21
  • [43] Work impact and cost-effectiveness of anti-CGRP monoclonal antibodies in patients with migraine
    Lazaro, C.
    Caronna, E.
    Alpuente, A.
    De la Torre, A.
    Torres, M.
    Pozo-Roisch, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 487 - 488
  • [44] Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
    Haanes, Kristian Agmund
    Edvinsson, Lars
    Sams, Anette
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [45] External validation of the predictive model of response to anti-CGRP monoclonal antibodies in patients with migraine
    Gonzalez Martinez, A.
    Sanchez-Rodriguez, C.
    Pagan, J.
    Fernandez Lazaro, I.
    Rodrigue-Vico, J. S.
    Jaimes Sanchez, A.
    Gomez Garcia, A.
    Casas Limon, J.
    Diaz de Teran, J.
    Sastre Real, M.
    Membrilla Lopez, J. A.
    Latorre, G.
    Calle de Miguel, C.
    Gil Luque, S.
    Trevino-Peinado, C.
    Quintas Gutierrez, S.
    Heredia, P.
    Garcia Azorin, D.
    Echavarria Iniguez, A.
    Guerrero Peral, A. L.
    Sierra-Mencia, A.
    Gonzalez Garcia, N.
    Porta-Etessam, J.
    Gago-Viega, A.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [46] Anti-CGRP monoclonal antibodies and peripheral sensitization: a study on Pressure Pain Threshold in migraineurs
    Garascia, G.
    Deodato, M.
    D'Acunto, L.
    Granato, A.
    Biaduzzini, F.
    Manganotti, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [47] In Response to Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents
    Charles, James A.
    HEADACHE, 2020, 60 (01): : 271 - 272
  • [48] Early clinical response in patients with migraine in treatment with anti-CGRP monoclonal antibodies: a possible "loading dose" effect?
    Ceccardi, Giulia
    di Cola, Francesca Schiano
    Bolchini, Marco
    Di Pasquale, Michele
    Rao, Renata
    Padovani, Alessandro
    CEPHALALGIA, 2023, 43 (1supp) : 253 - 254
  • [49] Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
    Pellesi, Lanfranco
    Guerzoni, Simona
    Pini, Luigi Alberto
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (06): : 534 - 547
  • [50] Patterns of response to anti-CGRP monoclonal antibodies after 6-months of treatment in resistant migraine patients
    Torres-Ferrus, M.
    Alpuente, A.
    Gine-Cipres, E.
    Caronna, E.
    Gallardo Lopez, V.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
12345